|
| Ziprasidone의 임상적 사용 지침 |
|
Seung Hwan Lee, MD1, Ung Gu Gang, MD2, Jae Jin Kim, MD3, Chan Hyung Kim, MD3,
Jung Seo Yi, MD4, Yeon Ho Joo, MD5, Kyung Sue Hong, MD6 and Jun Soo Kwon, MD2 |
|
|
|
|
| Abstract |
|
Ziprasidone is an atypical antipsychotic agent having an antagonistic effect on dopaminergic receptor (D2) and type2 serotonergic
receptor (5HT2). It has shown excellent efficacy against positive and negative symptoms of schizophrenia and better side effect
profiles compared to other atypical antipsychotics (i.e., lower metabolic syndrome rate, lower extrapyramidal symptoms rate, and
less somnolence, etc.). This article presents clinical guidelines for using ziprasidone focusing on four subtopics, i.e., ‘initiation
and titration’, ‘drug switch’, ‘drug compliance’, and ‘identifying the high priority patient’. The recommendations are based on
clinical literatures, expert consensus suggestions developed in Canada and Australia, Zeldox Consumer Medical Information, and
clinical experiences of the authors. Much more controlled and naturalistic clinical studies on ziprasidone use should be accumulated
to develop more evidence-based and comprehensive version of clinical guidelines. (Korean J Schizophr Res 2008;11:
97-106) |
| Key Words:
Ziprasidone,Clinical guideline,Dosage,Switching,Adverse effect |
|
PDF Links
Full text via DOI
Download Citation
